Organon & Co.

OGN

Healthcare Drug Manufacturers General

Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.

Revenue
−1.75%
EPS
+1.64%
Free cash flow
+118.8%
Total debt
−3.10%

Quarter to September 2026, against a year earlier

13.87 0.08 +0.58%
Market cap
$3.6B
P/E
17.3×
Fwd P/E
6.2×
Dividend yield
0.58%
F-score
5/9
ROIC
6.26%
Net debt / EBITDA
5.6×
Dividend safety
45/100

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Net Income
213.00 209.00 246.00 187.00

+8 more TTM periods

Operating Cash Flow
843.00 737.00 850.00 700.00
Investing cash flow
201.00 130.00 168.00 (390.00)
Financing cash flow
(242.00) (313.00) (524.00) (561.00)
Ending Cash
1,357.00 1,107.00 1,143.00 574.00

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 5 Nov 2026